PRX002, an investigational monoclonal antibody, may inhibit cell-to-cell transmission of alpha-synuclein and modify disease progression in Parkinson’s disease (PD), according to a study presented at the recent International Congress of Parkinson’s Disease and Movement Disorders in Vancouver. Researchers evaluated the use of PRX002 in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. The patient population consisted of 80 predominantly Caucasian males with mild to moderate PD. PRX002 was well tolerated and showed a rapid dose- and time-dependent reduction of alpha-synuclein levels of up to 97 percent after a single does. These observations were consistent after two additional monthly doses. A phase 2 study is planned to evaluate PRX002 as a disease-modifying treatment for PD.Next Story
Anti-Alpha-Synuclein Antibody Shows Early Potential as Parkinson’s DMT
Friday, June 09, 2017
You must be logged in to leave a comment.